{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:06:01Z","timestamp":1790741161768,"version":"4.1.0"},"reference-count":53,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T00:00:00Z","timestamp":1534982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Objective: Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Studies involving the human use of drugs labeled with deuterium suggest that these compounds may offer some advantages when compared with their nondeuterated counterparts. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs. Deutetrabenazine (Austedo, Teva Pharmaceutical Industries, Ltd) is the first deuterated drug to receive Food and Drug Administration approval. This deuterated form of the drug tetrabenazine is indicated for the treatment of chorea associated with Huntington\u2019s disease as well as tardive dyskinesia. Ongoing clinical trials suggest that a number of other deuterated compounds are being evaluated for the treatment of human diseases and not merely as research tools. Data Sources: A search of the MEDLINE (1946 to present) database was undertaken using the Ovid interface. The search was conducted using the heading deuterium and then limited to Administration &amp; Dosage, Adverse Effects, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, and Toxicity. Study Selection and Data Extraction: All articles were reviewed and those with human information were included. Review articles were likewise interrogated for additional published human data. Conclusions: Deuterated compounds may, in some cases, offer advantages over nondeuterated forms, often through alterations in clearance. Deuteration may also redirect metabolic pathways in directions that reduce toxicities. The approval of additional deuterated compounds may soon follow. Clinicians will need to be familiar with the dosing, efficacy, potential side effects, and unique metabolic profiles of these new entities.<\/jats:p>","DOI":"10.1177\/1060028018797110","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T06:54:46Z","timestamp":1535007286000},"page":"211-216","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":136,"title":["Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals"],"prefix":"10.1177","volume":"53","author":[{"given":"Edward M.","family":"Russak","sequence":"first","affiliation":[{"name":"University at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Bednarczyk","sequence":"additional","affiliation":[{"name":"University at Buffalo, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,8,23]]},"reference":[{"key":"bibr1-1060028018797110","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1351\/pac199971081593","volume":"71","author":"Rosman K","year":"1999","journal-title":"Pure Appl Chem"},{"key":"bibr2-1060028018797110","volume-title":"Paper presented at: Proceedings of the Fourth International Conference on Atomic Masses and Fundamental Constants","author":"Sanders JH"},{"key":"bibr3-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1103\/PhysRev.40.1"},{"key":"bibr4-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb03544.x"},{"key":"bibr5-1060028018797110","first-page":"308","volume-title":"Encyclopedia of Chemical Processing and Design","author":"Marter W","year":"1982"},{"key":"bibr6-1060028018797110","unstructured":"Harbeson SL, Tung RD. Deuterium medicinal chemistry: a new approach to drug discovery and development. http:\/\/www.concertpharma.com\/news\/documents__remove_me_Mar_2015_KMG\/MEDCHEMNEWSVol24No28-22PMay2014.pdf. Accessed August 13, 2018."},{"key":"bibr7-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1093\/acprof:oso\/9780198570264.001.0001"},{"key":"bibr8-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1201\/9781420028027"},{"key":"bibr9-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1002\/jlcr.3031"},{"key":"bibr10-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.12.1481"},{"key":"bibr11-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-12108-6"},{"key":"bibr12-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.042770"},{"key":"bibr13-1060028018797110","doi-asserted-by":"publisher","DOI":"10.7916\/D8M32W3H"},{"key":"bibr14-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biochem.7b00765"},{"key":"bibr15-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-017-0051-5"},{"key":"bibr16-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30236-5"},{"key":"bibr17-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.241497"},{"key":"bibr18-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-1993(16)30138-2"},{"key":"bibr19-1060028018797110","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S111352"},{"key":"bibr20-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.223768"},{"key":"bibr21-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2016.63"},{"key":"bibr22-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.178640"},{"key":"bibr23-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-17121-0_47"},{"key":"bibr24-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.01.016"},{"key":"bibr25-1060028018797110","unstructured":"Nuedexta [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals Inc; 2015."},{"key":"bibr26-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1089\/neu.2014.3766"},{"key":"bibr27-1060028018797110","first-page":"281A","volume":"60","author":"DeWitt SH","year":"2015","journal-title":"Hepatology"},{"key":"bibr28-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.171"},{"key":"bibr29-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1056\/nejm196902132800701"},{"key":"bibr30-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-014-1247-6"},{"key":"bibr31-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.07.018"},{"key":"bibr32-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1417832112"},{"key":"bibr33-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-628669"},{"key":"bibr34-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2012.06.004"},{"key":"bibr35-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1021\/ja410569g"},{"key":"bibr36-1060028018797110","unstructured":"U S National Library of Medicine, ClinicalTrials.gov. A first in human study of RT001 in patients with Friedreich\u2019s ataxia. NCT02445794. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02445794. Accessed August 13, 2018."},{"key":"bibr37-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1021\/jm4007998"},{"key":"bibr38-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1042\/cs0800277"},{"key":"bibr39-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90327-1"},{"key":"bibr40-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1079\/BJN19910060"},{"key":"bibr41-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)90177-6"},{"key":"bibr42-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2003.207"},{"key":"bibr43-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(81)90965-0"},{"key":"bibr44-1060028018797110","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.115.113464"},{"key":"bibr45-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1542\/peds.104.S3.633"},{"key":"bibr46-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(89)80159-3"},{"key":"bibr47-1060028018797110","first-page":"4","volume":"87","author":"Kahan FM.","year":"2009","journal-title":"Chem Eng News"},{"key":"bibr48-1060028018797110","unstructured":"Drug Discovery Today.com. Drug developers look to deuterated drugs as risk managed opportunity. http:\/\/www.drugdiscoverytoday.com\/view\/46297\/drug-developers-look-to-deuterated-drugs-as-risk-managed-opportunity\/. Published August 14, 2017. Accessed August 13, 2018."},{"key":"bibr49-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1039\/c7gc01740e"},{"key":"bibr50-1060028018797110","unstructured":"Thomson Reuters Micromedex Clinical Evidence Solutions. 2017: Red Book Drug References. Available at http:\/\/www.micromedexsolutions.com. Accessed August 25, 2018."},{"key":"bibr51-1060028018797110","unstructured":"Austedo [package insert]. North Wales, PA: Teva Pharmaceuticals USA Inc; 2017."},{"key":"bibr52-1060028018797110","unstructured":"Xenazine [package insert]. Deerfield, IL: Lundbeck Inc; 2017."},{"key":"bibr53-1060028018797110","doi-asserted-by":"publisher","DOI":"10.1038\/nm0613-656"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018797110","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028018797110","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018797110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:37Z","timestamp":1777374877000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018797110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,23]]},"references-count":53,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1177\/1060028018797110"],"URL":"https:\/\/doi.org\/10.1177\/1060028018797110","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,23]]}}}